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The semaphorin and plexin family of ligand and receptor proteins
provides important axon guidance cues required for development.
Recent studies have expanded the role of semaphorins and plexins
in the regulation of cardiac, circulatory and immune system func-
tion. Within the immune system, semaphorins and plexins regulate
cell–cell interactions through a complex network of receptor and
ligand pairs. Immune cells at different stages of development often
express multiple semaphorins and plexins, leading to multivariate
interactions, involving more than one ligand and receptor within
each functional group. Because of this complexity, the significance
of semaphorin and plexin regulation on individual immune cell
types has yet to be fully appreciated. In this work, we examined the
regulation of T cells by semaphorin 6D. Both in vitro and in vivo T
cell stimulation enhanced semaphorin 6D expression. However,
semaphorin 6D was only expressed by a majority of T cells during
the late phases of activation. Consequently, the targeted disrup-
tion of semaphorin 6D receptor–ligand interactions inhibited T cell
proliferation at late but not early phases of activation. This pro-
liferation defect was associated with reduced linker of activated T
cells protein phosphorylation, which may reflect semaphorin 6D
regulation of c-Abl kinase activity. Semaphorin 6D disruption also
inhibited expression of CD127, which is required during the mul-
tiphase antigen-presenting cell and T cell interactions leading to
selection of long-lived lymphocytes. This work reveals a role for
semaphorin 6D as a regulator of the late phase of primary immune
responses.
immune regulation  lymphocyte selection  response maturation
The important regulatory functions of semaphorin (Sema) andplexin (Plex) family members within the immune system have
only recently been appreciated (1–5). In our previous reports, we
demonstrated that mature dendritic cells (DCs) express
plexin-A1 (Plxna1), which regulates T cell activation (6, 7).
Based on these observations, we postulated that T cells express
a Sema protein that interacts with Plxna1 in a simple ligand–
receptor pairing. However, recent publications have revealed
that similar to the TNF, CD28, and B7 families, immune cells
express numerous Sema and Plex ligand–receptor pairs with
multiple proteins interacting within a functional group (8–12).
For example, during DC and T cell interactions, combinations of
the following known receptor–ligand pairs are expressed:
Plxna1–Sema3A, Sema3A–Plxna4, Plxna1–Sema6D, and Plxna4–
Sema6D. DCs express Plxna1 along with plexin-A4 (Plxna4),
semaphorin 3A (Sema3A), and the coreceptor for Plxna1 and
Plxna4, neuropilin-1 (Nrp1) (10, 13, 14). T cells express Sema3A,
semaphorin 6D (Sema6D), and Plxna4 (5, 10, 14–16). These
multiple Sema and Plex proteins mediate cell–cell contact
between DCs and T cells. Moreover, the expression patterns also
suggest the potential for homotypic pairings during T cell–T cell
contact or DC–DC contact. Finally, the identification of Sema
and Plex expression by multiple immune cell types increases the
potential for complex cell–cell interactions beyond a simple DC
and T cell model of regulation (11, 13). The multivariate
interactions of Sema and Plex proteins are difficult to charac-
terize, especially given that the majority of functional studies
have relied on knockout mice with potential developmental
disruptions in which multiple tissues, interactions, cell types, and
maturation states may be affected (12). Elucidating the function
of the individual Sema and Plex proteins will help to contextu-
alize the total receptor–ligand interactions that occur during an
immune response. Thus far, there have been no studies that
directly examine the role of Sema6D in the immune system.
Sema6D function has only been inferred by the examination of
DCs that lack Plxna1 expression (6, 7, 15). In light of the
Sema–Plex immune network complexity, we have characterized
the role of Sema6D in T cells by using reagents that directly
target Sema6D or the multiple Plex protein partners of Sema6D
in the context of an intact immune system. Our studies uncover
an unknown role of Sema6D in the late phase of a T cell primary
immune response.
Results
In Vitro Activation of CD4 T Cells Enhances Sema6D Expression. We
examined the expression of Sema6D by CD4 T cells after
activation. Murine splenic CD4 T cells were isolated and
stimulated in vitro with plate-bound anti-CD3 and -CD28 anti-
body (CD3/CD28) over a 24-h period. T cell activation was
monitored by IL-2 expression (Fig. 1A). We observed that the
expression of Sema6D mRNA is decreased after initial activa-
tion, similar to previous observations (15). However, by 12–24 h
after stimulation, Sema6D expression was increased over naı̈ve
levels (Fig. 1B). Public databases confirmed the expression of
Sema6D in both human and mouse T cells and that CD3/CD28
stimulation enhances Sema6D expression over a 48-h period
[supporting information (SI) Fig. S1]. Stimulation of CD4 T
cells by CD3/CD28 also produced an increased expression of
Sema6D protein on the cell surface. Although mRNA levels
were increased by 24 h, protein expression was not enhanced
until 96–120 h after CD3/CD28 stimulation (Fig. 1C). The T cell
activation was confirmed by enhanced expression of CD69 and
CD44 by 48 h after stimulation. We also observed enhanced
expression of Sema6D protein after CD3/CD28 stimulation of
MOG-specific 2D2 TCR transgenic (Tg) T cells (Fig. S1D).
Coculture of ovalbumin (OVA)-specific OTII TCR Tg T cells
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with OVA-loaded dendritic cells (DCs) also resulted in en-
hanced expression of Sema6D (data not shown).
Although the plexin and semaphorin receptor–ligand inter-
actions within the immune system appear to be complex, our
previous work with Plxna1 led us to examine interactions with
Sema6D. To identify cell–cell interactions mediated by Sema6D,
we produced a Sema6D-Ig fusion protein (Fig. S2 A–C).
Sema6D-Ig colocalized with Plxna1 on the cell surface of COS-7
cells and DCs. The association of Sema6D-Ig with COS-7 cells
or DCs required Plxna1 expression (Fig. S2 D–F). Thus, during
an immune response, DC Plxna1, along with other plexins, can
participate in cell–cell interactions mediated by Sema6D.
Inhibition of Sema6D Reduces a Late Phase of T Cell Activation in Vitro.
Previous studies using mice or cells deficient in a single Plex
protein have suggested a possible role for Sema6D within the
immune system. However, a definitive function of Sema6D
cannot be determined from these studies given that multiple
ligands and receptors are expressed that may interact with Plex
or Sema proteins. To target Sema6D function directly, we used
both an anti-Sema6D monoclonal antibody and a Sema6D-Ig
fusion protein to block Sema6D interactions during T cell
activation. OVA-specific CD4 OTII TCR Tg V5 T cells,
labeled with carboxyfluorescein diacetate succinimidyl ester
(CFSE), were cocultured with either OVA antigen-loaded DCs
(OVA-DC) or unloaded DCs (DC) for 6 days. The extent of T
cell proliferation was measured directly by analysis of CFSE
dilution, in which an intermediate level of CFSE labeling
(CFSEint) identifies early rounds of division, whereas a low level
of CFSE labeling (CFSElow) identifies more extensive division
occurring during later periods of proliferation. T cells not
exposed to antigen through coculture with unloaded DC did not
proliferate, remaining CFSEhigh (Fig. 2A). OTII T cells exposed
to antigen through coculture with OVA-DC for 6 days prolif-
erated for multiple divisions, indicated by CFSEint and CFSElow
phenotypes (Fig. 2 A). Treatment of the coculture with anti-
Sema6D antibody inhibited the amount of cell division specifi-
cally during the late periods of proliferation, reducing the
percentage of OTII T cells with a CFSElow phenotype but not a
CFSEint phenotype. The inhibited cell division at day 6 after
anti-Sema6D Ab treatment did not result from a defect in the
rate of proliferation at earlier time points (Fig. 2B). The
percentage of proliferating OTII T cells (diluted CFSE labeling)
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anti-CD3/CD28 Stimulation
Fig. 1. Activation enhances Sema6D expression in CD4 T cells. T cells were
stimulated with plate-bound anti-CD3 and -CD28 antibodies. (A and B) Splenic
CD4 T cells were isolated by magnetic bead selection to a purity of 90%.
RNA was isolated from cultures at 0, 6, 12, and 24 h after initiation and
analyzed by quantitative PCR for IL-2 and Sema6D expression. The results are
representative of three independent experiments. (C ) Protein expression of
CD28 and the activation markers CD69 and CD44 (black line) vs. an isotype
control (gray line) was determined by FACS analysis on CD4, TCR T cells
cultured for 48 h. Sema6D protein expression was determined at 48, 72, 96,
and 120 h after culture initiation. Black line, anti-Sem6D monoclonal Ab (R&D
Systems); dotted line, isotype control. The results are representative of six
independent experiments.
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Fig. 2. Targeting Sema6D inhibits T cell proliferation at a late phase of
activation. DCs that were loaded with whole OVA protein (OVA-DC) or
unloaded (DC) were cocultured with purified OTII T cells in vitro. Before
culture initiation, OTII T cells were labeled with CFSE. The dilution of CFSE was
determined by flow cytometry for TCR cells gated from V5 and CD4 cells
at day 2, 4, or 6. (A–C ) OVA-stimulated cultures were also treated with either
an anti-Sema6D monoclonal antibody (R&D Systems) or a control antibody. (B)
The percentage of proliferating cells was determined for TCR VB5 OTII T
cells. At day 6, a two-tailed t test of five samples for each treatment group was
performed. The P value was 0.05. (C ) IL-2 receptor expression was deter-
mined for TCR VB5 OTII T cells. (D) Sema6D-Ig was used as an alternative to
anti-Sema6D Ab treatment in vitro. The dilution of CFSE was determined by
flow cytometry for TCR cells gated from V5 and CD4 cells at day 6.
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treated cocultures at days 2, 4, and 6. The rate of proliferation
between the groups was similar from day 0 to day 4. However,
proliferation was significantly reduced between days 4 and 6 by
anti-Sema6D Ab (Fig. 2B). Moreover, anti-Sema6D Ab treat-
ment did not overtly affect cell viability or T cell activation
measured by expression of the IL-2 receptor (Fig. 2C). Thus,
anti-Sema6D Ab treatment inhibited late stages of proliferation
without affecting either early division or activation. We also
examined the possibility that blocking Sema6D imprinted T cells
with a defect that manifest only in later rounds of proliferation
by delaying anti-Sema6D Ab treatment. OTII T cells were
cocultured with OVA-DC, but anti-Sema6D treatment was
delayed until day 4. Late rounds of proliferation, measured on
day 6 as a CFSElow phenotype, were inhibited by the anti-
Sema6D Ab treatment administered on day 4 (Fig. S3A). Thus,
T cell proliferation can be inhibited after initial activation by a
late administration of anti-Sema6D Ab. As an alternative
method of Sema6D targeting, we also treated cocultures with a
Sema6D-Ig fusion protein for 6 days. Similar to the anti-Sema6D
Ab studies, Sema6D-Ig treatment did not affect initial T cell
proliferation indicated by a CFSEint phenotype but did inhibit
the late rounds of proliferation indicated by a CFSElow pheno-
type (Fig. 2D). Thus, blockade of Sema6D interactions with
either an antibody or a fusion protein reduced late T cell
proliferation.
Inhibition of Sema6D Disrupts Endogenous T Cell Signaling. Given the
abnormalities in T cell proliferation, we examined endogenous
signaling pathways associated with activation, specifically phos-
phorylation of linker of activated T cells (LAT). We analyzed the
pattern of phospho-LAT (pLAT) in OTII T cells stimulated with
DCs at day 3 and day 6 of coculture by using phosphospecific
f low cytometry (PhosphoFlow) techniques (17–19). Between the
coculture groups, we specifically compared T cells of equivalent
cell size, to enhance our resolution of activation-induced phos-
phorylation (Fig. 3A). We also set the detection of phosphory-
lation in relation to T cells cultured with unloaded DCs at both
day 3 and day 6. We detected phosphorylation of LAT after
stimulation with OVA-DC in 28% of T cells at day 3 and 42%
of T cells at day 6 of coculture (Fig. 3B). The observed increase
in the percentage of pLAT T cells is most likely derived from
the coculture conditions, given the dynamic nature of the DC–T
cell interactions. Treatment of the cocultures with Sema6D-Ig
did not affect pLAT detection at day 3 but did profoundly inhibit
the increased percentage of pLAT T cells observed at day 6
(Fig. 3B). The percentage increase in pLAT T cells between
days 3 and 6 was 50% in control Ig-treated coculture compared
with only 10% in the Sema6D-Ig treated group. Although
Sema6D-Ig treatment affected pLAT, it did not affect phos-
phorylation of the TCR CD3 chain (pCD3), which is one of
the first phosphorylation events associated with T cell activation
(Fig. 3C). These effects of Sema6D-Ig on cell signaling may be
explained by two recent reports. The first identified that Sema6D
can activate Abl kinase within heart tissue (16). The second
demonstrated that within T cells, Abl kinase regulates phos-
phorylation of LAT but not CD3 (20). We examined the activity
of Abl kinase by analyzing the phosphorylation of an Abl kinase
target, CrkL (pCrkL). Sema6D-Ig inhibited pCrkL at day 6 but
not day 3 (Fig. S3B). Collectively, these observations demon-
strate that Sema6D regulates specific T cell signaling pathways
that include pLAT and may occur by a direct activation of Abl
kinase at a late time point of T cell activation.
In Vivo Activation of CD4 T Cells Enhances Sema6D Expression. We
examined the expression of Sema6D during the course of a
primary response by tracking T cell activation in vivo with an
adoptive transfer model (Fig. 4A). The in vivo activation of the
OTII T cells was visualized as an expansion of donor CD45.2,
CD4, and TCR T cells within the population of CD45.1
congenic recipient splenocytes. Expansion of the OTII T cells
was observed by day 3 after immunization and continued
through day 7 (Fig. 4B). Expansion was correlated with a
characteristic decrease in IL-7 receptor (CD127) expression by
T cells during the early phases of the primary response (21–26).
During the later phases between days 4 and 7 (Fig. 4C), the
percentage of T cells expressing CD127 increased, similar to
reported observations. The percentage of T cells expressing
Sema6D increased with activation and reached a majority during
the late phases of the response, similar to CD127 (Fig. 4C). By
day 7, 70% of activated T cells expressed Sema6D. In contrast,
by day 3, 70% of T cells expressed the activation-induced
surface proteins, VLA4 (very late antigen 4) and ICOS (induc-
ible costimulator) (Fig. 4D) (27–30).
Sema6D Regulates T Cell Activation in Vivo. We examined the
impact of targeting Sema6D in vivo by using the OTII T cell
adoptive transfer model (Fig. 5A). Congenic hosts that received
OTII T cells were injected with Sema6D-Ig at days 1 and 4 after
immunization. The expansion of the CD45.2 OTII T cells was
analyzed at both an early and late phase of the response, days 4
and 7, respectively. Sema6D-Ig treatment did not affect T cell
activation at day 4 but did result in a significant reduction of
expansion at day 7 (Fig. 5 B and C). We also examined the impact
of Sema6D-Ig treatment on the expression of CD127 in vivo. T
cell expression of CD127 was not affected at day 4. However,
targeting Sema6D inhibited the increase of CD127 expression at
day 7 (Fig. 5D). As an alternative methodology, we used a
monoclonal antibody to target Sema6D in the context of a









































































































































































































































Fig. 3. Targeting Sema6D inhibits endogenous T cell signaling at a late phase
of activation. DCs that were loaded with whole OVA protein (OVA-DC) or
unloaded (DC) were cocultured with purified OTII T cells in vitro. OVA-
stimulated cultures were also treated with either the Sema6D-Ig fusion pro-
tein or a control Ig. PhosphoFlow analysis was done of LAT phosphorylation
(pLAT) and CD3 phosphorylation (pCD3) in T cells cocultured with DCs at
days 3 and 6. (A) To reduce nonspecific autofluoresence impact on pLAT
detection, TCR cells of similar cell size (FSC) were analyzed for each treatment
group. (B) The detection of pLAT was determined in reference to T cells
cocultured with unloaded DCs. Black line, anti-pLAT antibody; gray line,
intracell isotype control. (C ) The detection of pCD3 was determined in
reference to T cells cocultured with unloaded DCs. Black line, anti-pCD3
antibody; gray line, intracell isotype control. Results are representative of
three independent experiments.









2D2 TCR Tg T cells (Fig. S4A). In this model, antigen is
delivered by DCs injected directly into the CNS. Targeting of
Sema6D by anti-Sema6D antibody resulted in a reduced expan-
sion of 2D2 T cells in the CNS without a corresponding reduction
in the percentage of 2D2 T cells detected in the periphery (Fig.
S4 B–D). Thus, targeting Sema6D with either Sema6D-Ig
or anti-Sema6D antibody resulted in reduced T cell activation
in vivo.
Discussion
We have observed that Sema6D regulates T cell activation
during the late phases of an immune response. Recent studies
have underscored the importance of long-lasting interactions
between T cells and antigen presenting cells (31). Two-photon
studies have identified multiple phases of interactions, which
engender early proliferation and also regulate the late phases of
a primary response (32–35). Disruption of these interactions,
such as by loss of ICAM-1, can result in loss of a memory
response even in the presence of initial activation (36). The
effects of disrupting T cell interactions often are not observed
until many days after initial activation (37). Our studies dem-
onstrate that Sema6D regulates the late-phase activity of T cells
during a primary immune response. Future studies will identify
the interacting proteins that contribute to Sema6D regulation at
this late phase. Our analysis of Sema6D association with DCs
suggests that in the context of DC-T cell contact in vivo, Plxna1
and Sema6D probably mediate late-phase interactions. T cell
contact with other cell types during the late phases of a primary
immune response may be mediated by Sema6D interactions with
other proteins.
The ability of Sema6D to regulate T cell activation involves
modulation of endogenous signaling pathways. We have ob-
served that disrupting Sema6D interactions results in an inhi-
bition of LAT phosphorylation in T cells without a concomitant
inhibition of CD3 phosphorylation. Corresponding to the in-
hibition of late-phase proliferation, Sema6D targeting primarily
reduced late-phase pLAT signaling. Concomitantly, we also
observed a late-phase disruption of CrkL phosphorylation with
Sema6D-Ig treatment. Previous studies have reported that
Sema6D can activate Abl kinase and that within T cells, Abl
regulates phosphorylation of CrkL and LAT but not CD3 (16,





D2 D3 D4 D7
CD45.2
A




OVA in C.F.A. (100ug I.P. day 0)
OTII TCR Tg T cells
(CD45.2), 1x10 , I.V.6
Days 2-7: Host splenocyte isolation
for CD45.2+ OTII T cell expansion
B
23.43.51 72.232.4


































Fig. 4. Sema6D expression is enhanced by T cell activation in vivo. (A) OTII
T cells (CD45.2) were adoptively transferred to congenic (CD45.1) recip-
ients and the splenocytes analyzed at days 2, 3, 4, and 7 after injection and
immunization. (B) The expansion of OTII T cells was measured by flow
cytometry as the percentage of TCR CD4 CD45.2 cells in the isolated
splenocyte population. (C ) The expression of the IL-7 receptor (CD127) and
Sema6D on the CD45.2 OTII T cells was analyzed by flow cytometry at days
2, 3, 4, and 7. Black line, surface expression; gray line, isotype control. (D)
The percentage of CD45.2 OTII T cells expressing VLA4, ICOS and Sema6D
was determined by flow cytometry at days 2, 3, 4, and 7. The expression
values within the immune samples (I) are presented in relation to the
expression observed at day 2 in the naı̈ve samples (D2 N). Results are
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Days 4 and 7: Host splenocyte isolation
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D
Fig. 5. Targeting Sema6D inhibits late-phase T cell activation in vivo. (A)
OTII T cells (CD45.2) were adoptively transferred to congenic (CD45.1)
recipients, and the splenocytes were analyzed at days 4, and 7 after
injection and immunization. Recipients were treated with Sema6D-Ig or a
control Ig at days 0 and 4. (B) The expansion of TCR CD4 CD45.2 OTII T
cells was analyzed in vivo at days 4 and 7 after adoptive transfer. (C ) The
expansion of OTII T cells for eight replicate samples within each treatment
group was compared. A two-tailed t test comparing the Sema6D-Ig-treated
samples with either the immunized or control Ig groups returned a P value
of 0.05. (D) The expression of CD127 on OTII T cells was determined by
flow cytometry. At day 4, the percentage of the total CD45.2 T cells with
low CD127 expression is denoted. At day 7, the percentage of the total
CD45.2 T cells with high CD127 expression is shown. The results are
representative of two independent experiments.
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enhanced until the late phases of activation, it appears possible
that the late-phase inhibition of pLAT may derive directly from
a defect in Sema6D signaling by Abl kinase activity. However,
the regulation of Abl kinase activity within T cells is complex,
and future studies are required to elucidate fully the endogenous
T cell signaling pathways regulated by Sema6D.
The in vivo expression pattern of Sema6D is similar to the
pattern for CD127 expression during the late phases of an
immune response. Previous studies have documented a decrease
in CD127 expression by T cells during the early phases of a
primary response. In the later phases, as T cell are selected into
the memory pool, CD127 expression is increased. Inhibition of
this late-phase increase in CD127 expression results in defective
T cell memory (21, 24, 26). Intriguingly, we observed that
Sema6D targeting results in the inhibition of CD127 expression
by T cells during the late phase of an in vivo primary response.
This may be caused, in part, by the activity of Abl kinase
downstream of Sema6D. Abl kinase activity promotes IL-2
production, which is known to be required for CD127 expression
during the late phase of a primary immune response (20–22, 38).
Recent studies have demonstrated that inhibitors of Abl kinase,
such as Imatinib, inhibit CD127 expression by T cells and
memory responses while allowing initial phases of activation,
including proliferation, to occur (39). However, in contrast to
pan-T cell inhibitors, Sema6D targeting may specifically affect a
distinct activated population of T cells. Our analysis of in vivo T
cell activation demonstrated a differential expression pattern of
Sema6D between T cell subsets, with only low expression
detected on CD8 T cells or unactivated T cells throughout the
course of the primary response (data not shown). Thus,
the regulation of T cell activity by Sema6D may be restricted
to the activated CD4 T cell compartment.
Given the complexity of the Sema–Plex network, future
studies will be required to identify all of the functional interac-
tions that regulate specific immune functions. Early studies using
knockout models demonstrated a significant role for semaphor-
ins and plexins in directing immune system activity. Recent
observations of multiple receptor and ligand interactions, how-
ever, suggest a need for characterization of individual protein
function. Studies using Plxna1-deficient DCs and knockout
animals suggested that Sema6D, as a possible ligand, may
regulate immune activation. Subsequent studies have revealed
other ligands within the immune system for Plxna1, making
indirect conclusions regarding ligand function difficult. In our
studies directly examining the impact of Sema6D on T cells, we
have observed an important role for Sema6D in the late phases
of a primary immune response. The interacting partner for
Sema6D at this late phase may be Plxna1 or some other protein
yet to be identified. Future studies are required to comprehend
this complex network and to determine the Sema–Plex combi-
nations that can be manipulated as a treatment regime for
human disease. This work has identified Sema6D as an impor-
tant regulator of the late phase of a primary immune response,
and thus, treatment modalities involving Sema6D may enhance
vaccine development, reduce the impacts of autoimmunity, or
improve immune-based cancer therapies.
Materials and Methods
Mice. All experiments were performed with 8- to 12-week-old C57BL/6 mice
from Jackson Laboratories or B6-Ly5.2/Cr (CD45.1) mice from the National
Cancer Institute/National Institutes of Health. OT-II mice that express the
OVA[323–339]-specific TCR transgene on the C57BL/6 background were gen-
erous gifts from M. Croft (La Jolla Institute for Allergy and Immunology, La
Jolla, CA). All animal procedures were conducted in complete compliance with
the National Institutes of Health guidelines and are approved by the IACUC of
University of North Carolina, Chapel Hill.
SYBR Green Real-Time PCR. SYBR Green quantitative PCR Rox mix (Abgene) was
used for all quantitative PCR experiments. The following cycle conditions were
used: (i) 50° for 2 min; (ii) 95° for 15 min; (iii) 95° for 15 s, 56–57° for 15–30 s,
72° for 15–30 s, repeat 40 times; (iv) dissociation curve. Target genes were
calculated in reference to -actin: forward, 5-agggctatgctctccctcac-3; and re-
verse, 5-ctctcagctgtggtggtgaa-3. The Sema6D primers used were: forward,
5-cagaagcatgggagatggat-3; and reverse, 5-gccacccatgtcgtttttac-3.
Cloning and Production of Mouse Sema6D-Ig Fusion Protein. A full-length cDNA
of isoform 6 of Sema6D (Sema6D-6) was isolated, cloned, sequenced, and
verified as Sema6D. A cDNA fragment containing the extracellular region of
Sema6D was subcloned into a modified pcDNA3.1 vector (Invitrogen) con-
taining a human IgG1 fragment (Hinge-CH2-CH3). Generation of stable ex-
pression cells was performed with DHFR-Chinese hamster ovary cells (CHO/
DG44; Invitrogen) selected in medium supplemented with 100 nM
methotrexate (Sigma).
Flow Cytometry. Detection of Sema6D was performed with a monoclonal
anti-Sema6D antibody (R&D Systems). Phosphospecific flow cytometry was
performed according to the techniques developed by Gary Nolan’s group and
adopted by BD PharMingen (19). Before surface staining, cell samples were
fixed for 10 min at 37°C in 20 volumes of prewarmed (37°C) Phospho Fix
buffer I (catalog no. 557870; BD PharMingen) or Cytofix/Cytoperm (catalog
no. 54722; BD PharMingen). Cells were then stained for surface antigens
followed by washing and permeabilization for 20–30 min in prechilled
(20°C) PhosFlow Perm buffer III (catalog no. 558050; BD Pharmingen). After
permeabilization, cells were washed and incubated with a mixture of Fc
receptor blocking antibodies for 15 min. The appropriate antibodies for
detection of intracellular phosphospecific epitopes (BD PharMingen) were
then added to each sample and incubated for an additional 30 min. Staining
was quantified with a FACSCalibur (Becton Dickinson). Fluorescence signals
were detected by four-decade logarithmic amplification; FSC and SSC were
detected on a linear scale. Data were analyzed with FlowJo software (FlowJo).
In Vitro CD3/CD28 Stimulation and Coculture Conditions. For stimulation of T
cells, 5 g/ml anti-mouse CD3 and anti-mouse CD28 were added in PBS to cell
culture plates for overnight coating at 4°C. Primary T cells isolated from
spleens were incubated at 1  106 cells per ml in 2 ml per well of a 6-well coated
plate. For in vitro coculture stimulation, OTII TCR Tg (OVA-specific) T cells were
incubated with immature DCs at a ratio of 5:1 in RPMI medium 1640. OTII T
cells were isolated from the spleens of Tg mice and purified by negative
selection with T enrichment columns (R&D Systems). Isolated T cells were
labeled with CFSE (Molecular Probes) or unlabeled before culture. Murine
bone marrow-derived DCs were isolated from bone marrow and grown in
vitro for maturation as described (6, 7). For OVA loading, DCs were resus-
pended at a concentration of 1  106 cells in 1 ml of cRPMI with 10 g/ml whole
OVA protein. The final concentration of CFSE used for T cell labeling was 15
M in RPMI medium 1640 with 10–20 million cells per ml.
Anti-Sema6D Antibody and Sema6D-Ig Fusion Protein Treatment. Anti-Sema6D
monoclonal Ab (R&D Systems) was used at a final concentration of 10 g/ml
for in vitro and ex vivo treatment of T cells. Anti-Sema6D Ab was given every
3rd day of in vitro culture. The Sema6D-Ig fusion protein was used at a final
concentration of 5 g/ml for in vitro treatment. In vivo, Sema6D-Ig was
injected i.p. at a concentration of 100 g of per mouse. Intraperitoneal
injections were given at days 1 and 4 after adoptive transfer.
Adoptive Transfer and Immunization. After isolation of OTII splenocytes from
mice, RBCs were lysed by incubation with an ammonium chloride Tris solution.
The percentage of Tg OTII T cells within a population was determined by
staining 2  105 cells with anti-V2 and anti-V5 in 5% bovine calf serum in
balanced salt solution at 4°C and analyzed by a Becton Dickinson FACSCalibur.
For each primary transfer, 1  106 CD45.2 OTII T cells were injected by tail
vein into B6-CD45.1 recipient mice. At the time of adoptive transfer, some
recipients were also injected i.p. with 100 g of OVA protein emulsified in
Complete Freund’s adjuvant. Typically, three mice were used per experimental
group.
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